Carbidopa hydrateProduct ingredient for Carbidopa
- Name
- Carbidopa hydrate
- Drug Entry
- Carbidopa
Carbidopa presents a chemical denomination of N-amino-alpha-methyl-3-hydroxy-L-tyrosine monohydrate. It potently inhibits aromatic amino acid decarboxylase (DDC) and due to its chemical properties, it does not cross the blood-brain barrier. Due to its activity, carbidopa is always administered concomitantly with levodopa. An individual formulation containing solely carbidopa was generated to treat nausea in patients where the combination therapy levodopa/carbidopa is not efficient reducing nausea.9
The first approved product by the FDA containing only carbidopa was developed by Amerigens Pharmaceuticals Ltd and approved on 2014.10 On the other hand, the combination treatment of carbidopa/levodopa was originally developed by Watson Labs but the historical information by the FDA brings back to the approval of this combination therapy developed by Mayne Pharma in 1992.11
- Accession Number
- DBSALT001834
- Structure
Structure for Carbidopa hydrate (DBSALT001834)
- Synonyms
- (−)-L-α-hydrazino-3,4-dihydroxy-α-methylhydrocinnamic acid monohydrate / (2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid hydrate / (2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid monohydrate / (S)-(−)-carbidopa hydrate / (S)-carbidopa hydrate / (αS)-α-hydrazino-3,4-dihydroxy-α-methylbenzenepropanoic acid monohydrate / Carbidopa monohydrate / Carbidopum monohydricum / L-α-(3,4-dihydroxybenzyl)-α-hydrazinopropionic acid monohydrate